passages.id: split_4_validation_1147_passage
passages.type: progene_text
passages.text: Recently , the efficacy of abciximab and other glycoprotein IIb / IIIa inhibitors was proven in the treatment of acute coronary syndromes and after PTCA , and their early use in patients with acute myocardial infarction is presently under evaluation .